Why Clovis Oncology Fell 7.1% in August
Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed to the company sharing good and bad news with investors during in its second-quarter report.
Here's a review of the headline numbers from the company's second quarter:
Financial updates aside, Clovis also had several other highlights to share with investors:
Source: Fool.com
Bristol-Myers Squibb Stock
€37.60
0.620%
Currently there is a rather positive sentiment for Bristol-Myers Squibb with 11 Buy predictions and 3 Sell predictions.
As a result the target price of 70 € shows a very positive potential of 86.19% compared to the current price of 37.6 € for Bristol-Myers Squibb.
